Successful oral midodrine therapy for treatment of refractory postoperative chylothorax in an infant

Area of Science:

• Pediatric Cardiology
• Thoracic Surgery
• Pharmacology

Background:

• Refractory chylothorax is a challenging postoperative complication in infants with congenital heart disease (CHD).
• Current management strategies for refractory chylothorax have limitations and can be associated with significant morbidity and mortality.
• The case involves a 10-month-old infant diagnosed with 22-mosaic trisomy and a complex coarctation of the aorta.

Observation:

• The infant developed persistent chylothorax following surgical repair of complex congenital heart disease.
• Conventional treatments for chylothorax were ineffective, leading to a refractory state.
• The infant's condition presented a critical management challenge due to its refractory nature.

Findings:

• Successful treatment of refractory chylothorax was achieved using midodrine, an oral alpha-1-adrenoreceptor agonist.
• Midodrine administration led to the resolution of chylothorax in this pediatric patient.
• This represents a novel therapeutic approach for managing refractory chylothorax post-cardiac surgery.

Implications:

• Midodrine shows potential as an adjunctive therapy for refractory chylothorax in the postoperative setting.
• This case highlights a new therapeutic avenue for a difficult-to-manage complication in pediatric cardiac surgery.
• Further research is warranted to explore the efficacy and safety of midodrine in a larger cohort of patients with refractory chylothorax.